Drug intelligence / Profile preview

CAR-exosome

Development stage: Preclinical
Lead developer: INOVIQ
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

CAR-exosome is a preclinical-stage, cell-free allogeneic extracellular vesicle (EV)-based therapy being developed by INOVIQ. The platform involves engineering exosomes to express Chimeric Antigen Receptors (CARs) on their surface, allowing them to specifically recognize and target tumor antigens. Unlike traditional CAR-T cell therapies, CAR-exosomes are non-cellular, potentially offering advantages in safety (reduced risk of cytokine release syndrome), stability, and the ability to penetrate solid tumors. INOVIQ is currently evaluating these therapeutics for the treatment of triple-negative breast cancer (TNBC) and glioblastoma.

Other names: CAR-Exosomecell-free allogeneic EV-based therapy

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on CAR-exosome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-exosome.

Explore the full profile